Market Newsdesk

KUALA LUMPUR, Malaysia, July 20, 2023 (GLOBE NEWSWIRE) — BioNexus Gene Lab Corp. (“BioNexus” or the “Company”), an emerging company in the business of selling chemical raw materials in the Southeast Asia region and the development of safe, effective, and non-invasive liquid biopsy tests for early diagnosis and personalized health management, today announced the pricing of its Public Offering (the “Offering”) of 1,250,000 shares of common stock at a price of $4.00 per share for total gross proceeds of $5 million before deducting underwriting discounts and commissions and offering expense.

In addition, the Company has granted the underwriter an option, exercisable within 45 days from the closing date, to purchase up to an additional 187,500 shares at the public offering price, less underwriting discounts and commissions. The shares have been approved for listing on NASDAQ Capital Market and are expected to commence trading on July 20, 2023, under the symbol “BGLC.” The offering is expected to close on or about July 24, 2023, subject to the satisfaction of customary closing conditions.

The Offering is being conducted on a firm commitment basis. Network 1 Financial Securities, Inc. is acting as the sole book-running manager for the Offering.

Ortoli Rosenstadt LLP is acting as U.S. counsel to BioNexus, and VCL Law LLP is acting as counsel to the underwriter with respect to the Offering.

A registration statement on Form S-1, as amended (File No. 333-269753) relating to the Offering was previously filed with the U. S. Securities and Exchange Commission (“SEC”) by the Company, and subsequently declared effective by the SEC on July 19, 2023. The Offering is being made only by means of a prospectus, forming a part of the registration statement. A final prospectus relating to the Offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Electronic copies of the final prospectus related to the Offering may be obtained, when available, from Network 1 Financial Securities, Inc., 2 Bridge Avenue, Suite 241, Red Bank, New Jersey 07701; Attention Adam Pasholk, email [email protected] or by calling +1 (800) 886-7007.

Before you invest, you should read the final prospectus and other documents the Company has filed or will file with the SEC for more complete information about the Company and the Offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About
Bionexus
Gene Lab Corp.

BioNexus Gene Lab Corp. is developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of disease risks derived from evidence-based research to minimize treatment costs and improve patient management on his current health status. Our non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.

Furthermore, through our wholly owned subsidiary Chemrex Corporation Sdn Bhd., we focus on selling chemical raw materials for manufacturing industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. For more information, visit www.bionexusgenelab.com.

Safe Harbor Statement

This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.

Company
Contact:

[email protected]

Investor Relations Contact:

Matthew Abenante, IRC
President
Strategic Investor Relations, LLC
Tel: 347-947-2093
Email: [email protected]

NEW YORK, July 20, 2023 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of Funko, Inc..

Shareholders who purchased shares of FNKO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/funko-loss-submission-form/?id=42345&from=3

CLASS PERIOD: May 6, 2022 to March 1, 2023

ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) Funko was experiencing significantly larger delays in implementing its enterprise resource planning (“ERP”) software than it was disclosing to investors; (ii) having moved into a new warehouse without functioning ERP software in place would lead to dramatically higher costs and poorer inventory management practices; and (iii) Funko’s inability to efficiently operate the new distribution center would have a substantial, undisclosed impact on Funko’s earnings before interest, taxes, depreciation, and amortization (“EBITDA”) margin.

DEADLINE: August 1, 2023 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/funko-loss-submission-form/?id=42345&from=3

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of FNKO during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is August 1, 2023. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company’s stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903

ATHENS, Greece, July 20, 2023 (GLOBE NEWSWIRE) — Capital Product Partners L.P. (NASDAQ: CPLP) today announced that before the NASDAQ market opens on July 28, 2023, CPLP will release financial results for the second quarter ended June 30, 2023.

On the same day, Friday, July 28, 2023 CPLP will host an interactive conference call at 9:00 am Eastern Time to discuss the financial results.

Conference
Call
Details:

Participants should dial into the call 10 minutes before the scheduled time using the following numbers: +1 877 405 1226 (US Toll-Free Dial In) or +1 201 689 7823 (US and Standard International Dial In). Please quote “Capital Product Partners” to the operator and/or conference ID 13740260. Click here for additional participant International Toll-Free access numbers.

Alternatively, participants can register for the call using the call me option for a faster connection to join the conference call. You can enter your phone number and let the system call you right away. Click here for the call me option.

Slides
and
Audio
Webcast

There will also be a live, and then archived, webcast of the conference call and accompanying slides, available through the Company’s website. To listen to the archived audio file, visit our website http://ir.capitalpplp.com/ and click on Webcasts & Presentations under our Investor Relations page. Participants to the live webcast should register on the website approximately 10 minutes prior to the start of the webcast.

About
Capital
Product
Partners
L.P.

Capital Product Partners L.P. (NASDAQ: CPLP), a Marshall Islands master limited partnership, is an international owner of ocean-going vessels. CPLP currently owns 23 vessels, including seven latest generation LNG/Cs, 12 Neo-Panamax container vessels, three Panamax container vessels and one Capesize bulk carrier vessel.

For more information about the Partnership, please visit our website: www.capitalpplp.com.

Forward-Looking
Statements

The statements in this press release that are not historical facts may be forward-looking statements (as such term is defined in Section 21E of the Securities Exchange Act of 1934, as amended). These forward-looking statements involve risks and uncertainties that could cause the stated or forecasted results to be materially different from those anticipated. Unless required by law, we expressly disclaim any obligation to update or revise any of these forward-looking statements, whether because of future events, new information, a change in our views or expectations, to conform them to actual results or otherwise. We assume no responsibility for the accuracy and completeness of the forward-looking statements. We make no prediction or statement about the performance of our common units.

CPLP-F

Contact Details:

Capital
GP
L.L.C.
Jerry Kalogiratos
CEO
Tel. +30 (210) 4584 950
E-mail: [email protected]

Capital GP L.L.C.
Nikos Kalapotharakos
CFO
Tel. +30 (210) 4584 950
E-mail: [email protected]

Investor
Relations
/
Media

Nicolas Bornozis
Capital Link, Inc. (New York)
Tel. +1-212-661-7566
E-mail: [email protected]

Source: Capital Product Partners

WOBURN, Mass., July 20, 2023 (GLOBE NEWSWIRE) — NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its Q2 2023 business and financial highlights before the opening of the market on July 27, 2023. The Company will host a conference call at 8:00 a.m., Eastern Time on July 27, 2023.

For participants who wish to access the Q2 2023 Conference Call live via telephone and be able to ask questions, please register in advance here. Upon registering, a dial-in and unique PIN will be provided on screen and via email to join the call. An audio-only webcast of the call, along with the earnings press release and accompanying condensed financial statements, may be accessed in the Investors section of the Company’s website at www.NeuroMetrix.com. Following the conference call, a replay of the call will be available for one year on the Company’s Investors section of the website.

About NeuroMetrix

NeuroMetrix is a commercial stage healthcare company that develops and commercializes neurotechnology devices to address unmet needs in the chronic pain and diabetes markets. The Company’s products are wearable or hand-held medical devices enabled by proprietary consumables and software solutions that include mobile apps, enterprise software and cloud-based systems. The Company has two commercial brands. Quell^® is a wearable neuromodulation platform. DPNCheck^® is a point-of-care screening test for peripheral neuropathy. For more information, visit www.NeuroMetrix.com.

NeuroMetrix, Inc.
Thomas T. Higgins
SVP and Chief Financial Officer
[email protected]

Source: NeuroMetrix, Inc.

NEW YORK, July 20, 2023 (GLOBE NEWSWIRE) — Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions, will report its financial results for the quarterly period ended June 30, 2023 after the close of the market on Thursday, August 3, 2023.

The company will host a conference call at 4:45 P.M. Eastern Time (1:45 P.M. Pacific Time) and issue a press release regarding its financial results prior to the start of the call.

Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the passcode 265484. International participants may access the call by dialing 1.973.413.6106 and using the same passcode.

An audio replay of the call will be available through Thursday, August 10, 2023 and may be accessed by dialing 1.800.332.6854 (U.S. participants) or 1.973.528.0005 (international participants) with the passcode 265484.

A live webcast and archive of the call will be available from the Events and Presentations section of the Company’s website at http://investors.progyny.com.

About Progyny
Progyny (Nasdaq: PGNY) is a leading fertility benefits management company. We are redefining fertility and family building benefits, proving that a comprehensive and inclusive solution can simultaneously benefit employers, patients, and physicians. 

Our benefits solution empowers patients with education and guidance from a dedicated Patient Care Advocate (PCA), provides access to a premier network of fertility specialists using the latest science and technologies, reduces healthcare costs for the nation’s leading employers, and drives optimal clinical outcomes. We envision a world where anyone who wants to have a child can do so.

Headquartered in New York City, Progyny has been recognized for its leadership and growth by CNBC Disruptor 50, Modern Healthcare’s Best Places to Work in Healthcare, Financial Times, INC. 5000, and Crain’s Fast 50 for NYC. For more information, visit www.progyny.com.

For Further Information, Please Contact:


Investors:
James Hart
[email protected]

Media:
Selena Yang
[email protected]

LAFAYETTE, Colo., July 20, 2023 (GLOBE NEWSWIRE) — The Center for Disease Analysis Foundation (CDA Foundation) announced today that it received an $8 million grant from Gilead Sciences (Nasdaq: GILD) as part of Gilead’s Relink grant program. CDA Foundation will disperse the grant to qualifying tax-exempt organizations to contact diagnosed but untreated patients with hepatitis C virus (HCV) or hepatitis B virus (HBV) infection to bring them back into care.

Despite the availability of existing treatment and vaccination options; in the United States an estimated 2.4 million people are living with HCV, and 850,000 are estimated to be living with HBV, according to the U.S. Department of Health and Human Services. Both viruses are responsible for increasing rates of cirrhosis, liver cancer, liver failure and premature deaths. According to CDA Foundation’s research, the risk of developing cancer for someone infected with HCV or HBV infection is the same as someone who smokes one pack of cigarettes per day. HCV and HBV are associated not only with liver cancer but also increased risk of lymphoma, diabetes, insulin resistance, renal disease, fatigue, cognitive impairment, depression, impaired quality of life, arthritis, fibromyalgia and cardiovascular disorders.

Recognizing the growing continued risk of viral hepatitis, the World Health Organization set a global target to eliminate viral hepatitis as a major public health threat by 2030. Despite the availability of oral drugs with high cure rates for HCV and effective therapies for HBV, this goal has been impeded because many patients diagnosed with viral hepatitis are unaware of their infection, do not seek follow-up care, or delay treatment. According to a recent study by U.S. CDC, less than 30% of all Medicaid, Medicare, and private insurance recipients initiate treatment within one year of being diagnosed in the U.S. The Relink grant program aims to identify and work to bridge the gaps that remain in linking patients back to necessary care and treatment.

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19 and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

“Hepatitis B and C viruses are highly cancer causing. The Gilead Relink grant is an important example of how public and private partnership can shape viral hepatitis elimination programs that will help the United States achieve WHO targets by 2030,” said Homie Razavi, Founder and Managing Director, CDA Foundation. “In order to improve viral hepatitis patient outcomes in the United States, we must ensure that individuals not only have access to but are also guided toward affordable and effective prevention, care and treatment services.”

“Gilead has been committed to improving the lives of people living with liver disease for more than two decades, and we are thrilled to expand our support to healthcare organizations through the new Gilead Relink grant program,” said Macky Natha, Vice President, Medical Affairs, Gilead Sciences. “As we work toward eliminating viral hepatitis as a public health threat by 2030, we must address barriers to treatment by relinking the people who have been lost in the process, and that’s what the CDA Foundation and other impactful organizations will help accomplish through this program.”

For more information, please visit https://cdafound.org/relink or contact CDA Foundation at [email protected].

About Center for Disease Analysis Foundations

CDA Foundation is a non-profit organization that seeks to help eliminate HBV and HCV globally by 2030 by providing countries across the world with verified epidemiological data, disease burden and economic impact modeling, smart intervention strategies, access to affordable diagnostics and treatments, innovative financing, and knowledge-sharing partnerships to eliminate these deadly infections. It works with more than 110 countries globally and 26 US states on their viral hepatitis elimination programs. It is headquartered in Lafayette, Colorado.

VICTORIA, British Columbia, July 20, 2023 (GLOBE NEWSWIRE) — Today, TELUS and the Victoria Cool Aid Society announced the expansion of their partnership through TELUS’ Health for Good program, with the launch of a second new mobile health clinic to help address the increasing need for primary health care and provide support for people experiencing homelessness in the capital region. To date, the existing mobile clinic has enabled more than 14,000 patient encounters from citizens throughout the greater Victoria area. The addition of the brand new Cool Aid Mobile Health Clinic, powered by TELUS Health, will double patient capacity, providing much needed services to the over 1,500 individuals experiencing homelessness on any given night in Victoria. Our new Cool Aid Mobile Health Clinic will expand the program’s reach and service offerings to provide support for sex workers and referrals for dental and physiotherapy services. With the help of local partners, it will also dedicate one day each week to assisting Indigenous community members.

“At TELUS, we are driven by our collective desire to leverage our technological and human innovation to enable better health outcomes for people around the world,” said Jill Schnarr, Chief Social Innovation and Communications Officer, TELUS. “Through our longstanding partnership with the Victoria Cool Aid Society, we are continuing to remove many of the barriers facing underserved and marginalized populations in Victoria by providing access to primary healthcare, mental wellness and addiction support services. By combining technology with human compassion, we are bringing healthcare directly to the communities and people who need it most, reminding our fellow citizens that they’re not alone and helping create a friendlier future for all.”

The new, custom built Cool Aid Mobile Health Clinic, powered by TELUS Health, was designed by ékm Architecture and is equipped with TELUS Wi-Fi network connectivity and TELUS Health electronic medical record (EMR) solutions. The mobile health clinic is staffed by physicians who specialize in addictions medicine, registered nurses with certified practice (expanded scope), as well as health outreach clinicians and peer workers, and will deliver various trauma-informed services, including:

• Primary healthcare such as routine testing, contraception, women’s health services, STI treatment, harm reduction services, and mental health care and counseling
• Specialized support services for sex workers; and
• Administrative aid, including helping clients complete BC Housing documentation.

“Bringing a second mobile clinic to the capital region further expands our community health centre model of care and provides services for those who experience barriers to accessing health care,” said Mary Chudley, director of health and support services at Cool Aid. “Many individuals, including those who are under-housed or experiencing homelessness, have not had access to primary care in years or do not have a documented medical history that can be referenced by healthcare practitioners. Our existing mobile clinic serves 25 locations on a bi-weekly rotational basis, and we expect this second clinic to more than double our capacity.”

With the addition of the second Cool Aid Mobile Health Clinic, more community partners are able to benefit, like the Aboriginal Coalition to End Homelessness society – a key community partner that provides culturally supportive affordable housing and services to help end Aboriginal homelessness on Vancouver Island.

“The Cool Aid mobile health clinics are critical in assisting us to meet the care of the people we serve and house.” said Fran Hunt-Jinnouchi, executive director for the Aboriginal Coalition to End Homelessness. “We are so appreciative of the high standard of care received as a result of this partnership and its weekly visits. It brings consistency of service, and access to an Indigenous physician at two of our culturally supportive housing sites on a weekly basis.”

This additional mobile health clinic was made possible with the support of Victoria Foundation, Connor, Clark & Lunn Financial Group, The Jawl Foundation and Times Colonist and demonstrates the power of businesses working together with community organizations to address pressing societal issues.

For more information about TELUS Health for Good, visit telus.com/healthforgood.

About TELUS Health for Good

Since 2014, TELUS Health for Good has been connecting underserved individuals to the medical and mental health care they need using the power of technology. Backed by a commitment of $13 million through 2026, TELUS Mobile Health Clinics have now supported over 170,000 patient visits across 25 Canadian communities since inception in 2014. Equipped with TELUS electronic medical records technology, and fuelled by compassion, our Mobile Health Clinics provide essential primary medical care to individuals living on the streets. The program also supports women experiencing marginalization with access to free TELUS Health MyCare Counselling sessions and supports low-income older adults to live more independently and enjoy peace of mind with subsidized access to TELUS LivingWell Companion™.

About
 TELUS

TELUS (TSX: T, NYSE: TU) is a dynamic, world-leading communications technology company with more than $18 billion in annual revenue and over 18 million customer connections spanning wireless, data, IP, voice, television, entertainment, video, and security. Our social purpose is to leverage our global-leading technology and compassion to drive social change and enable remarkable human outcomes. Our longstanding commitment to putting our customers first fuels every aspect of our business, making us a distinct leader in customer service excellence and loyalty. The numerous, sustained accolades TELUS has earned over the years from independent, industry-leading network insight firms showcase the strength and speed of TELUS’ global-leading networks, reinforcing our commitment to provide Canadians with access to superior technology that connects us to the people, resources and information that make our lives better.

Operating in 32 countries around the world, TELUS International (TSX and NYSE: TIXT) is a leading digital customer experience innovator that designs, builds, and delivers next-generation solutions, including AI and content moderation, for global and disruptive brands across strategic industry verticals, including tech and games, communications and media, eCommerce and fintech, banking, financial services and insurance, health care, and others.

TELUS Health is a global health care leader, which provides employee and family primary and preventive health care and wellness solutions. Our TELUS team, along with our 100,000 health professionals, are leveraging the combination of TELUS’ strong digital and data analytics capabilities with our unsurpassed client service to dramatically improve remedial, preventive and mental health outcomes covering 67 million lives, and growing, around the world. As the largest provider of digital solutions and digital insights of its kind, TELUS Agriculture & Consumer Goods enables efficient and sustainable production from seed to store, helping improve the safety and quality of food and other goods in a way that is traceable to end consumers.

Driven by our determination and vision to connect all citizens for good, our deeply meaningful and enduring philosophy to give where we live has inspired TELUS and our team to contribute $1.6 billion, including 2.2 million days of service since 2000. This unprecedented generosity and unparalleled volunteerism have made TELUS the most giving company in the world. Together, let’s make the future friendly.

For more information about TELUS, please visit telus.com, follow us at @TELUSNews on Twitter and @Darren_Entwistle on Instagram.

About the Victoria Cool Aid Society
The Victoria Cool Aid Society believes that everyone deserves home, health and community. We create opportunities for people who are homeless or living in poverty and we make a difference through housing, health and dental care, community, and emergency shelters. Founded in 1968, Cool Aid helps more than 12,000 people in the Capital region every year, at 20 locations in Victoria, Saanich and Langford, including more than 7,000 Community Health Centre patients. For more information about Cool Aid, visit coolaid.org.

For media inquiries, please contact:

Saara Rahikka
TELUS Media Relations
[email protected]

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/3b6b9a47-6147-42f1-b108-e17ee3c88547

https://www.globenewswire.com/NewsRoom/AttachmentNg/15724022-aa67-4a80-9288-a6583529a913

https://www.globenewswire.com/NewsRoom/AttachmentNg/c436eb95-9146-4d1d-80c0-f3beea760ae1